Oral atenolol compared to oral propranolol for infantile hemangioma
Introduction Infantile hemangioma is the most frequent benign vascular tumor in childhood, with an incidence of 3 to 10%. When patients require treatment, oral propranolol, a non-selective lipophilic beta-blocker, is usually considered the therapy of choice. However, its use has been associated with...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medwave Estudios Limitada
2023-12-01
|
| Series: | Medwave |
| Subjects: | |
| Online Access: | https://www.medwave.cl/puestadia/resepis/2753.html |
| _version_ | 1797361614284914688 |
|---|---|
| author | Victor Meza Viteri Ligia Aranibar |
| author_facet | Victor Meza Viteri Ligia Aranibar |
| author_sort | Victor Meza Viteri |
| collection | DOAJ |
| description | Introduction Infantile hemangioma is the most frequent benign vascular tumor in childhood, with an incidence of 3 to 10%. When patients require treatment, oral propranolol, a non-selective lipophilic beta-blocker, is usually considered the therapy of choice. However, its use has been associated with several adverse events related to its β-2 action and its ability to cross the blood-brain barrier. Because of this, oral atenolol, a hydrophilic β-1 receptor-selective beta-blocker, may represent a valid treatment alternative. Nonetheless, there is still controversy regarding the efficacy and safety of atenolol when compared with propranolol as monotherapy for this condition.
Methods We searched Epistemonikos, the largest database of systematic reviews in health science, which is maintained by screening multiple sources of information, including MEDLINE/PubMed, EMBASE, and Cochrane, among others. Data were extracted from the identified reviews, data from the primary studies were analyzed, a meta-analysis was performed, and a summary table of the results was prepared using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method.
Results Nine systematic reviews were identified, including 10 primary studies and three randomized trials. The three randomized trials were included in the analysis of this investigation.
Conclusion The use of oral atenolol compared with oral propranolol as monotherapies may result in little or no difference in terms of likelihood of complete remission, decrease in Hemangioma Activity Score, likelihood of post-treatment relapse, and risk of adverse events and severe adverse events, in infantile hemangioma (low certainty of evidence). |
| first_indexed | 2024-03-08T15:57:11Z |
| format | Article |
| id | doaj.art-08edf81dc3284a719a5483be905d97c8 |
| institution | Directory Open Access Journal |
| issn | 0717-6384 |
| language | English |
| last_indexed | 2024-03-08T15:57:11Z |
| publishDate | 2023-12-01 |
| publisher | Medwave Estudios Limitada |
| record_format | Article |
| series | Medwave |
| spelling | doaj.art-08edf81dc3284a719a5483be905d97c82024-01-08T16:29:35ZengMedwave Estudios LimitadaMedwave0717-63842023-12-012311e2753e275310.5867/medwave.2023.11.2753Oral atenolol compared to oral propranolol for infantile hemangiomaVictor Meza Viteri0https://orcid.org/0000-0003-3615-8136Ligia Aranibar1Departamento de Dermatología, Facultad de Medicina, Universidad de los Andes, Santiago, ChileDepartamento de Dermatología, Universidad de Chile, Santiago, Chile; Clínica Universidad de los Andes, Departamento de Dermatología, Universidad de los Andes, Santiago, ChileIntroduction Infantile hemangioma is the most frequent benign vascular tumor in childhood, with an incidence of 3 to 10%. When patients require treatment, oral propranolol, a non-selective lipophilic beta-blocker, is usually considered the therapy of choice. However, its use has been associated with several adverse events related to its β-2 action and its ability to cross the blood-brain barrier. Because of this, oral atenolol, a hydrophilic β-1 receptor-selective beta-blocker, may represent a valid treatment alternative. Nonetheless, there is still controversy regarding the efficacy and safety of atenolol when compared with propranolol as monotherapy for this condition. Methods We searched Epistemonikos, the largest database of systematic reviews in health science, which is maintained by screening multiple sources of information, including MEDLINE/PubMed, EMBASE, and Cochrane, among others. Data were extracted from the identified reviews, data from the primary studies were analyzed, a meta-analysis was performed, and a summary table of the results was prepared using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method. Results Nine systematic reviews were identified, including 10 primary studies and three randomized trials. The three randomized trials were included in the analysis of this investigation. Conclusion The use of oral atenolol compared with oral propranolol as monotherapies may result in little or no difference in terms of likelihood of complete remission, decrease in Hemangioma Activity Score, likelihood of post-treatment relapse, and risk of adverse events and severe adverse events, in infantile hemangioma (low certainty of evidence).https://www.medwave.cl/puestadia/resepis/2753.htmlinfantile hemangiomapropranololatenololepistemonikosgrade |
| spellingShingle | Victor Meza Viteri Ligia Aranibar Oral atenolol compared to oral propranolol for infantile hemangioma Medwave infantile hemangioma propranolol atenolol epistemonikos grade |
| title | Oral atenolol compared to oral propranolol for infantile hemangioma |
| title_full | Oral atenolol compared to oral propranolol for infantile hemangioma |
| title_fullStr | Oral atenolol compared to oral propranolol for infantile hemangioma |
| title_full_unstemmed | Oral atenolol compared to oral propranolol for infantile hemangioma |
| title_short | Oral atenolol compared to oral propranolol for infantile hemangioma |
| title_sort | oral atenolol compared to oral propranolol for infantile hemangioma |
| topic | infantile hemangioma propranolol atenolol epistemonikos grade |
| url | https://www.medwave.cl/puestadia/resepis/2753.html |
| work_keys_str_mv | AT victormezaviteri oralatenololcomparedtooralpropranololforinfantilehemangioma AT ligiaaranibar oralatenololcomparedtooralpropranololforinfantilehemangioma |